Washington Healthcare Update

McGuireWoods LLP

This Week: Congress remains on recess…CMS released Final MACRA rule and 2017 Medicare Advantage Star Ratings…Zika and Mylan’s EpiPen still raise issues.

1. Congress


FDA Supports Expanded Authority Over Cosmetics

In an Oct. 5 letter to Senator Dianne Feinstein (D-CA), the Food and Drug Administration (FDA) says its current legal authority over cosmetics is limited and expressed appreciation for a Senate effort to increase the agency’s regulatory power over the cosmetic industry, including recall authority for such products.

Senator Feinstein along with Senator Susan Collins (R-ME) introduced the Personal Care Products Safety Act to protect consumers and streamline industry compliance by strengthening the FDA’s authority to regulate the ingredients in personal care products.

“The Administration recognizes the need to strengthen FDA’s regulatory program for cosmetics, and the President’s budget in the past few years has requested authority to require cosmetic firms to register their establishments and products with FDA and to pay a user fee,” FDA states. “We appreciate your leadership in sponsoring legislation to provide these authorities as well as others to address limitations in FDA’s ability to oversee the safety of cosmetic products.”

The agency explains that all reporting of adverse events by companies for cosmetic products is voluntary, unlike the case for other FDA-regulated products. FDA asserts the lack of reliable information makes it difficult to assess problems with cosmetics and can delay efforts to respond to the complaint.

A systematic review process called for by the Senate bill would allow FDA to restrict harmful ingredients under a more consumer-protective safety standard, the agency says. Under the legislation, FDA says it would be able to restrict the use of a cosmetic ingredient if there is not enough information to ensure there would not be harm.

FDA’s authority is additionally limited by the lack of legal requirements to make cosmetic companies report to the agency about their products and safety data, or the location of their manufacturing facilities. The president’s budget also requested mandatory registration and reporting, the agency says, which would allow FDA to know what cosmetics are on the market and what ingredients they include.

The agency also criticizes the industry-funded panel of medical and scientific experts, the Cosmetic Ingredient Review, that assesses the safety of cosmetic ingredients based on the data in the published literature and information that is voluntarily provided by the cosmetic industry.

FDA clarifies that it does not have the authority to require a recall of cosmetics that are in violation of the Food, Drug, and Cosmetic Act. Rather, the agency currently has to go through the Department of Justice to pursue seizure of adulterated or misbranded products and injunctions against firms that violate the law.

The Senate bill would require FDA to evaluate a minimum of five cosmetic ingredients per year for safety and appropriate use. The bill would also provide FDA recall authority for cosmetics; require adverse event reporting to the agency within 15 days; require annual manufacturer registration; direct FDA to issue guidance on good manufacturing practices for cosmetics; and authorize the agency to collect user fees from cosmetic manufacturers.

Senate Finance Democrats Release Report on Opioid Addiction and Treatment Shortfalls

On Oct. 10, Senate Finance Committee Democrats released a report on opioid addiction and treatment shortfalls in the United States. The authors criticize Republicans for blocking Democrat-sponsored amendments to provide CARA funding—one allocating the full $920 million requested, and one providing $600 million—as evidence of Republicans’ resistance to funding the program. Democrats also hold up what they view as the inadequacy of the $7.1 million in funding for CARA passed as part of the continuing resolution.

Medicaid policies are also put under the spotlight in the report. Democrats say access to residential care has been limited by an interpretation of the Medicaid Institutions for Mental Diseases (IMD) exclusion that prohibits the use of federal Medicaid matching funds for payments to residential treatment facilities.

The report asks for Congress to authorize the $920 million in mandatory funds proposed in President Obama’s budget request for the Substance Abuse and Mental Health Services Administration (SAMHSA). The $920 million would be used to fund two-year State Targeted Response Cooperative Agreements.

Under the agreements, states would be eligible for grants based on need and strength of strategies in addressing the opioid crisis, including: addressing barriers to treatment; training and approving treatment providers; supporting Medication-Assisted Treatment; eliminating costs of under- and uninsured patients; providing treatment and coverage for those leaving prison or other rehabilitative settings; enhancing prevention through evidence-based methods; supporting telehealth in rural areas; and integrating health IT to support identification of patients with opioid use disorders.

Senate Judiciary Committee Chairman Questions Mylan Settlement Details

Sen. Chuck Grassley (R-IA), chairman of the Senate Judiciary Committee is requesting more information about the unreleased $465 million settlement between the Justice Department and Mylan over EpiPen Medicaid rebates. Grassley wants to know how much states are supposed to receive from Mylan’s reported settlement, and he wants to know when and how CMS warned Mylan that it misclassified EpiPen as a generic. Grassley questions whether the reported deal fairly treats states. Mylan may have failed to pay more than $700 million to state Medicaid programs over the past five years, he said, much more than the $465 million for which Mylan said the Justice Department settled.

Mylan announced the $465 million settlement on its website Oct. 7, but the Justice Department released no information. According to Mylan’s statement, the company admits no wrongdoing and is negotiating a so-called corporate integrity agreement with the HHS Inspector General Office. Also, the Securities and Exchange Commission seeks “communications with the CMS and documents concerning Mylan products sold and related to the Medicaid Drug Rebate Program,” according to an SEC filing.

Mylan says the settlement resolved all potential rebate liability claims by government agencies over the classification of EpiPen as a generic. Drugmakers pay 13 percent rebates on the average manufacturer price of generics in the Medicaid Drug Rebate Program. For brand and single-source drugs, companies pay a 23.1 percent rebate or the difference between average manufacturer price and a drug’s best price, increased by an additional rebate when a drug’s price rises faster than inflation. Those additional price concessions for brand drugs, which do not apply to generics, are important in the case of EpiPen because the product’s price has risen more than 400 percent since 2007. Also, Mylan has given significant discounts to state education programs. Mylan says its EpiPen4Schools program gave schools more than 700,000 free epinephrine auto-injectors since 2012. The SEC filing states that EpiPen will be categorized as a generic until next April.

2. Administration

CDC Announces Another Zika Zone Detected in Miami Area

On Oct. 13, the CDC announced it is working with Florida health officials to investigate at least five new cases of locally transmitted Zika virus infection in Miami-Dade County. Florida officials announced a new area of active Zika transmission, which is about one square mile. Three of the cases involve people who live there; the other two work or have visited there. State health officials say this new neighborhood and the previously identified section of Miami Beach are the only known areas of active transmission.

CDC recommends that pregnant women avoid travel to both of the active transmission areas.

HHS Finalizes the New Medicare Quality Payment Program

On Oct. 14, HHS finalized its policy implementing the Merit-based Incentive Payment System (MIPS) and the Advanced Alternative Payment Model (APM) incentive payment provisions in the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), collectively referred to as the Quality Payment Program. The new Quality Payment Program will gradually transform Medicare payments for more than 600,000 clinicians across the country.

The final rule with comment period offers a fresh start for Medicare by centering payments around the care that is best for the patients, providing more options to clinicians for innovative care and payment approaches, and reducing administrative burden to give clinicians more time to spend with their patients, instead of on paperwork.

For more information, click here.

CMS Announces New Initiative to Increase Clinician Engagement

On Oct. 13, CMS announced a new initiative to improve the clinician experience with the Medicare program. This new long-term effort aims to reshape the physician experience by reviewing regulations and policies to minimize administrative tasks and seek other input to improve clinician satisfaction. The initiative will be led by senior physicians within CMS who will report to the Office of the Administrator.

Acting Administrator Andy Slavitt appointed Dr. Shantanu Agrawal to lead the development of the function and implementation, which will cover documentation requirements and existing physician interactions with CMS, among other aspects of provider experiences. To ensure CMS is hearing from physicians on the ground, each of the 10 CMS regional offices will oversee local meetings to take input from physician practices within the next six months and regular meetings thereafter. CMS will then release a report with targeted recommendations to the CMS Administrator in 2017. Three of CMS’s regional Chief Medical Officers—Dr. Barbara Connors in Philadelphia, Dr. Ashby Wolfe in San Francisco and Dr. Richard Wild in Atlanta—will serve as regional champions of the initiative.

The first action is the launch of an 18-month pilot program to reduce medical review for certain physicians while continuing to protect program integrity. Under the program, providers practicing within specified Advanced Alternative Payment Models (APMs) will be relieved of some scrutiny under certain medical review programs. CMS identified Advanced APMs as a potential opportunity for this pilot because participating clinicians share financial risk with the Medicare program. After the results of the pilot are analyzed, CMS will consider expansion along various dimensions including additional Advanced APMs, specialties and provider types.

For more information, click here.

CMS Releases 2017 Medicare Star Ratings

According to CMS, nearly 70 percent of Medicare Advantage enrollees will be in plans that receive at least four stars for quality in 2017.

Just over half of private Medicare customers signed up for plans that received at least four stars in 2014. But the new figure decreased slightly from this year, when just over 70 percent of the 17 million-plus Medicare Advantage customers enrolled in the high-quality plans.

Medicare Advantage plans that receive at least four stars for quality are eligible for bonus payments, while those that consistently receive less than three stars can be eliminated from the program. Just two plans—operated by Tenet Healthcare Corporation and Health Care Service Corporation—are in danger of having their contracts terminated at the end of 2017 for poor performance, according to CMS.

There has been similar improvement in quality ratings for prescription drug plans. Just over 40 percent of Medicare beneficiaries who enroll in stand-alone prescription drug plans are expected to be in plans with at least four stars next year. This is up from just 9 percent who were enrolled in such high-performing plans in 2014.

There are expected to be 18.5 million individuals enrolled in private Medicare plans next year, representing about one-third of all beneficiaries. Medicare open enrollment starts on Oct. 15 and runs through Dec. 7.

For more information, click here.

3. State Activities

Massachusetts: Health Care Spending Was Worse Than Initially Reported

Health care spending in Massachusetts last year was worse than initially reported. The state’s health care spending increased 4.1 percent for last year, up from the 3.9 percent that was initially reported. This is also more than the 3.6 percent growth target set by a 2012 cost containment law. Massachusetts revised the rate after Harvard Pilgrim Health Care found errors in reporting it had earlier submitted that omitted $117 million in spending. The new figures suggest the state has not made much improvement in controlling health spending. Massachusetts spent $57.4 billion on health care in 2015 and has one of the highest medical costs in the country.

Minnesota: House Republicans Propose Response to Premium Increases

Minnesota House Republicans are proposing a new plan to respond to individual market premium increases for 2017 that will range from 50 to 67 percent on average. State lawmakers say they should use roughly $35 million that is left over from Minnesota’s high-risk pool to insulate consumers from the rate hikes, and they argue that the tax currently funding the state-based exchange should be cut by half, saving $22 million over three years.

Nebraska: Federal Officials Approve Plan to Manage Medicaid Services

Federal officials have approved a plan to expand Medicaid managed care in Nebraska. Under Heritage Health, starting in 2017 almost all Medicaid and CHIP enrollees will receive behavioral health, physical health and pharmacy services under a statewide managed care program. Nebraska awarded contracts to three insurers as part of the initiative: United Healthcare, Centene and WellCare. Nursing home and other long-term care will not be included in the program.

New York: Health Department Proposes Medicaid Coverage for Transgender Youths

The New York State Health Department issued a proposed rule that would allow Medicaid to cover youth transgender health treatment. Under the proposal, Medicaid would cover hormone therapy for minors with gender dysphoria. Last year, New York began covering hormone treatments for adults. However, Medicaid coverage for those treatments is currently prohibited for minors.

Washington: CMS Agrees to Five-Year Waiver to Reform Care Delivery in Medicaid

CMS and Washington state have agreed to a new five-year waiver to reform care delivery in Medicaid. According to the state, the 1115 demonstration will allow for up to $1.5 billion in federal funding over the five-year period, most of which will be provided through a Delivery System Reform Incentive Payment program. The waiver’s three main initiatives seek to change the Medicaid delivery system through an existing community health collaboration, expand care options for beneficiaries receiving long-term services and supports, and address housing and employment needs for vulnerable populations. CMS sent a letter to the state announcing the agreement but details are still being finalized.

4. Regulations Open for Comment

IRS, Treasury Release Proposed Rule on QHP Benchmarks

The IRS and Treasury Department, in a proposed rule released July 6, proposed to alter how qualified health plan (QHP) benchmarks are determined so that they account for the costs of pediatric dental benefits. If finalized, the rule would go into effect for the 2019 plan year.

Although pediatric dental care is one of the 10 “essential health benefits” that plans are required to cover under the Affordable Care Act (ACA), several plans do not include such coverage, and consumers instead buy stand-alone dental products. Meanwhile, the marketplace determines the amount of tax credits a family can receive to cover the cost of coverage based on the second-cheapest silver-level plan.

However, as the proposed rule said, “because qualified health plans that do not offer pediatric dental benefits tend to be cheaper than qualified health plans that cover all ten essential health benefits, the second lowest-cost silver plan (and therefore the premium tax credit) for taxpayers purchasing coverage through a Marketplace in which stand-alone dental plans are offered is likely to not account for the cost of obtaining pediatric dental coverage.”

Treasury and IRS added that the existing rules “frustrate” the goal of making all essential health benefits affordable to those receiving premium tax credits, so the administration wants to update its interpretation to ensure all 10 services are addressed.

“Consistent with this interpretation, the proposed regulations provide that for taxable years beginning after December 31, 2018, if an Exchange offers one or more silver-level qualified health plans that do not cover pediatric dental benefits, the applicable benchmark plan is determined by ranking (1) the premiums for the silver-level qualified health plans that include pediatric dental benefits offered by the Exchange and (2) the aggregate of the premiums for the silver-level qualified health plans offered by the Exchange that do not include pediatric dental benefits plus the portion of the premium allocable to pediatric dental benefits for stand-alone dental plans offered by the Exchange,” the proposal said.

The rule aims to create the ranking by adding the premium for the lowest-cost silver plan that does not include a pediatric dental benefit to the premium for the cheapest stand-alone dental plan, and the premium for the second-cheapest silver plan without pediatric dental benefits to that of the second-lowest stand-alone dental plan. The second-cheapest amount from this combined ranking would be the taxpayer’s applicable benchmark plan premium, the rule said.

HHS Proposes Updates to Title X Rules

On Sept. 2, HHS proposed to preclude Title X grant recipients from using criteria in their selection of family planning providers that are unrelated to the ability to deliver services effectively.

Since 2011, 13 states have attempted to restrict participation by family planning providers in Title X based on factors unrelated to their ability to provide services. The Title X program provides funding for certain family planning services, including STD screening and treatment, but funding is not used to pay for abortions. Although Planned Parenthood is not mentioned by name in the proposed rule, it has often been the subject of defunding actions by states and Congress.

In the proposed rule, HHS said the effects already felt by the restrictions in many states justify the department’s rulemaking. HHS said grant recipients that do not provide services directly would also be required to follow the updated standards when choosing subrecipients.

HHS also proposed that a tiered structure governing how funds are distributed would not be allowed unless it can be proven that a provider in a top tier delivers Title X services more effectively than a lower-tier provider. According to the Guttmacher Institute, a research organization that supports reproductive rights, four states have a priority system for distributing family planning funds, which often disadvantages family planning centers.

CMS Proposes Changes to Risk Adjustment in 2018 Marketplace Rules

On Aug. 29, CMS issued the proposed annual Notice of Benefit and Payment Parameters for 2018, which outlines additional steps to strengthen the Health Insurance Marketplace. CMS is issuing this rule earlier in the calendar year in order to provide more certainty to the Marketplace as it continues to mature.

Beginning in 2017, the proposed policies will take steps to strengthen the risk adjustment program. First, the rule proposes updates beginning in 2017 to better reflect the risk associated with enrollees who are not enrolled for a full 12 months. Second, beginning in 2018, the rule proposes to use prescription drug utilization data to improve the predictive ability of CMS’s risk adjustment models. Third, also beginning in 2018, the rule proposes to establish transfers that will help to better spread the risk of high-cost enrollees, a change that would improve the risk-sharing benefits of the program.

In addition to the improvements to risk adjustment, the proposed rule contains other provisions to improve the Marketplace consumer experience and strengthen the individual and small group markets as a whole. The proposed rule would give consumers additional tools for assessing the networks of competing plans; broaden availability of this year’s new standardized plan options by accommodating state cost-sharing rules; and create consumer protections for consumers enrolling through the direct enrollment channel. The proposed rule would also create multiple child age bands that address instances in which consumers could face large premium changes after turning age 21; amend the guaranteed renewability regulations to provide additional flexibility for issuers to remain in an insurance market in certain situations; and codify several special enrollment periods that are already available to consumers in order to ensure the rules are clear and to limit abuse. It also seeks information on a number of suggestions offered by issuers, consumers, providers and others on further improving the risk pool, such as additional changes to special enrollment period policies or outreach; clarifying coordination of benefit rules between Medicare, Medicaid and the Marketplace; and providing greater certainty on the amount of user fee revenue spent on education and outreach.

To see the proposed rule, click here.

5. Reports

GAO Releases Report on Aligning Health Quality Measures

On Oct. 13, GAO released a report on the hurdles to measuring and rewarding quality health care. GAO found that while HHS is working to better align its health care quality measures across programs and private payers, it needs to set key priorities for those efforts and develop more meaningful measures. More specifically, GAO recommends that HHS 1) prioritize its development of electronic quality measures and related data elements for the core measures it and private payers have agreed to use, and 2) comprehensively plan, including setting timelines for, its efforts to develop more meaningful quality measures.

To see the report, click here.

Kaiser Report Finds Medicaid Spending Growth Slowed Down in 2016

According to a Kaiser Family Foundation Survey released Oct. 13, spending under the Medicaid program grew much more slowly in fiscal year 2016 as the initial effects of the ACA’s coverage expansion began to wear off. Total Medicaid spending by the federal and state governments grew at a rate of 10.5 percent in fiscal year 2015 as Obamacare led to a surge in enrollment. In fiscal year 2016, spending growth declined to under 6 percent. Officials project that fiscal year 2017 spending will grow even more slowly, at a rate of 4.5 percent.

In future years, researchers wrote, trends in Medicaid are more likely to be influenced by the economy, cost pressures from rising prescription drug prices and state policies, rather than Obamacare coverage expansion. However, the cost burden of Medicaid coverage is shifting toward the states because of the ACA requirement they pick up 5 percent of expansion costs starting in 2017.

Though total Medicaid spending growth is on the decline, states’ spending on the program is projected to climb by 4.4 percent on average in fiscal year 2017, up from 2.9 percent the previous year.

Thirty-one states and the District of Columbia have expanded their programs to cover people with incomes up to 138 percent of the federal poverty level, as called for under the Affordable Care Act. Expansion states eventually have to cover 10 percent of the costs. Many states—Arizona, Arkansas, Colorado, Illinois, Indiana, Louisiana, New Hampshire and Ohio—are relying on provider taxes to cover all or parts of their share.

The survey also examined how states are using Medicaid managed care, managing prescription drug costs, addressing opioid abuse and implementing delivery system reforms.

To see the survey, click here.

Report Looks at Trends in Hospital Inpatient Drug Costs

According to an industry-funded report, hospital spending on drugs for inpatients increased by more than 23 percent from 2013 to 2015, and more than 90 percent of hospitals said price increases are straining their budgets. The report, commissioned by the American Hospital Association (AHA) and the Federation of American Hospitals, found that hospitals’ drug spending far exceeded the 9.9 percent growth in retail pharmacy spending over the same time.

American Hospital Association CEO Rick Pollack and Federation of American Hospitals CEO Chip Kahn called on drug companies to restrain the price increases and highlighted proposals to boost pricing transparency and improve generic competition.

The report looked at responses from more than 700 hospitals. It also examined data from two group-purchasing organizations on 28 drugs chosen either because they had huge price increases or they were high-spending products for hospitals.

Most of those drugs were older off-patent products routinely used at hospitals, as opposed to costly new cancer treatments, for instance, which are typically administered to outpatients. About half of the 28 had no active generic competition, giving the drugmakers an effective monopoly.

To see the report, click here.

Deloitte Releases Report Examining Consumer Priorities in Health Care

Deloitte recently released its 2016 survey examining consumer priorities in health care. The survey of about 1,800 people found that the importance of relationships with health care providers remains the top priority for consumers. Moreover, respondents generally said they did not use or understand health care digital tools that were available to them. “Given the investment in digital resources and the experiences consumers are having with digital capabilities outside of health care, it might seem like digital tools are an essential part of individual health care management (scheduling, billing, disease management, etc.). We found that this isn’t necessarily the case today,” Deloitte wrote in an accompanying analysis.

Study Shows How Soda Companies Fund National Health Groups

A study examining how the Coca-Cola Company and PepsiCo have tried to block efforts to reduce soda consumption finds that they lobbied against 29 public health bills from 2011 to 2015 and financially sponsored 96 national health organizations, many of which are tasked with fighting the country’s obesity epidemic. The entities include trade associations like the American Medical Association, the American Diabetes Association and the American Academy of Pediatrics, but also government agencies like HHS, the NIH and the CDC. “It is recommended that organizations find alternative sources of revenue in order to stop indirectly and inadvertently increasing soda consumption and causing substantial harm to Americans,” the authors from Boston University write.

To see the study, click here.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McGuireWoods LLP | Attorney Advertising

Written by:

McGuireWoods LLP

McGuireWoods LLP on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.